世界卫生组织II型无排卵女性的治疗策略:系统综述与网状Meta分析
该系统综述与网状Meta分析比较了8种一线促排卵治疗对WHO II型无排卵女性的效果,纳入54项随机对照试验共7173名女性。与单用氯米芬相比,来曲唑和氯米芬联合二甲双胍的妊娠率更高,来曲唑是唯一活产率显著更高的治疗,二甲双胍的多胎妊娠率更低。
要点
- 与单用氯米芬相比,来曲唑和氯米芬联合二甲双胍的妊娠率更高。
- 与单用氯米芬相比,来曲唑是唯一活产率显著更高的治疗。
- 与单用氯米芬相比,二甲双胍的多胎妊娠率更低。
核心结论
- 在WHO II型无排卵女性中,来曲唑和氯米芬联合二甲双胍在妊娠方面优于单用氯米芬。
- 与单用氯米芬相比,来曲唑是唯一显示活产率显著更高的治疗。
研究设计与样本
- 系统综述与网状Meta分析,检索Cochrane对照试验中心注册库、Medline和Embase至2016年4月11日。
- 纳入54项随机对照试验,共7173名WHO II型无排卵女性,比较8种促排卵治疗。
主要发现
- 所有药物治疗在妊娠和排卵方面均优于安慰剂或无干预。
- 与单用氯米芬相比,来曲唑的妊娠率更高(比值比1.69,95%置信区间1.33至2.14)。
- 与单用氯米芬相比,氯米芬联合二甲双胍的妊娠率更高(比值比1.71,95%置信区间1.28至2.27)。
- 与单用氯米芬相比,来曲唑的活产率更高(比值比1.67,95%置信区间1.11至2.49)。
- 与单用氯米芬相比,二甲双胍的多胎妊娠率更低(比值比0.22,95%置信区间0.05至0.93)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effectiveness of alternative first line treatment options for women with WHO group II anovulation wishing to conceive. DESIGN: Systematic review and network meta-analysis. DATA SOURCES: Cochrane Central Register of Controlled Trials, Medline, and Embase, up to 11 April 2016. STUDY SELECTION: Randomised controlled trials comparing eight ovulation induction treatments in women with WHO group II anovulation: clomiphene, letrozole, metformin, clomiphene and metformin combined, tamoxifen, gonadotropins, laparoscopic ovarian drilling, and placebo or no treatment. Study quality was measured on the basis of the methodology and categories described in the Cochrane Collaboration Handbook. Pregnancy, defined preferably as clinical pregnancy, was the primary outcome; live birth, ovulation, miscarriage, and multiple pregnancy were secondary outcomes. RESULTS: Of 2631 titles and abstracts initially identified, 54 trials reporting on 7173 women were included. All pharmacological treatments were superior to placebo or no intervention in terms of pregnancy and ovulation. Compared with clomiphene alone, both letrozole and the combination of clomiphene and metformin showed higher pregnancy rates (odds ratio 1.69, 95% confidence interval 1.33 to 2.14; 1.71, 1.28 to 2.27; respectively). Letrozole led to higher live birth rates when compared with clomiphene alone (1.67, 1.11 to 2.49). Metformin led to lower multiple pregnancy rates compared with clomiphene alone (0.22, 0.05 to 0.93). CONCLUSIONS: In women with WHO group II anovulation, letrozole and the combination of clomiphene and metformin are superior to clomiphene alone in terms of pregnancy. Compared with clomiphene alone, letrozole is the only treatment showing a significantly higher rate of live birth. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42015027579. READERS' NOTE: This is the second version of this paper. The original version was corrected following the retraction of two studies and removal of another which were ineligible (references 40, 41, and 75 of the original paper). These studies are not shown in this version. A tracked changes version of the original version is attached as a supplementary file to the correction notice, which explains the issue further.
引用
- Wang R, Kim BV, van Wely M, et al. Treatment strategies for women with WHO group II anovulation: systematic review and network meta-analysis. BMJ. 2017. PMID: 28143834. doi:10.1136/bmj.j138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。